Mechanistic role of miR-375 in regulating PDPK1 to promote progression of small bowel neuroendocrine tumors: a silico analysis
Abstract Background The incidence of small bowel neuroendocrine tumors (SBNETs) is steadily increasing, new therapies are urgently needed to prolong the overall survival of patients. Objective This study aimed to identify diagnostic and therapeutic candidate markers for SBNETs. Methods Expression pr...
Saved in:
| Main Authors: | Tao Ren, Lu Zhou, Zhenlong Li, Mingmei Pan, Xueqiong Han |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-06-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-025-02872-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Predictive factors for persistent thrombocytopenia after peptide receptor radioligand therapy in enteropancreatic neuroendocrine tumors
by: Romain Ferrara, et al.
Published: (2025-05-01) -
Peptide receptor radionuclide therapy with 177Lu-DOTATATE for metastatic neuroendocrine tumor occurring in association with multiple endocrine neoplasia type 1 and cushing's syndrome
by: Chinna Naik, et al.
Published: (2017-04-01) -
Evaluation of using small volume of interest regions for clinical kidney dosimetry in 177Lu-DOTATATE treatments
by: Jehangir Khan, et al.
Published: (2025-07-01) -
Blood-based transcriptomic biomarkers for response to [177Lu]Lu-DOTA-TATE therapy in neuroendocrine tumors
by: Hyunpil Sung, et al.
Published: (2025-08-01) -
Prevalence of hitherto unknown brain meningioma detected on 68Ga-DOTATATE positron-emission tomography/computed tomography in patients with metastatic neuroendocrine tumor and exploring potential of 177Lu-DOTATATE peptide receptor radionuclide therapy as single-shot treatment approach targeting both tumors
by: Rahul V. Parghane, et al.
Published: (2019-04-01)